GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins

Cohen, 2001, The renaissance of GSK3, Nat. Rev. Mol. Cell Biol., 2, 769, 10.1038/35096075 Grimes, 2001, The multifaceted roles of glycogen synthase kinase 3 in cellular signaling, Prog. Neurobiol., 65, 391, 10.1016/S0301-0082(01)00011-9 Eldar-Finkelman, 2002, Glycogen synthase kinase 3, Trends Mol. Med., 8, 126, 10.1016/S1471-4914(01)02266-3 Kaytor, 2002, The GSK3β signaling cascade and neurodegenerative disease, Curr. Opin. Neurobiol., 12, 275, 10.1016/S0959-4388(02)00320-3 Doble, 2003, GSK-3, J. Cell Sci., 116, 1175, 10.1242/jcs.00384 Ding, 2002, Wnt signal transduction, Trends Biochem. Sci., 27, 327, 10.1016/S0968-0004(02)02137-0 Li, 2002, Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection, Bipolar Disord., 4, 137, 10.1034/j.1399-5618.2002.40201.x Bijur, 2001, Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta, J. Biol. Chem., 276, 37436, 10.1074/jbc.M105725200 Crowder, 2000, Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal, J. Biol. Chem., 275, 34266, 10.1074/jbc.M006160200 Culbert, 2001, GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity, FEBS Lett., 507, 288, 10.1016/S0014-5793(01)02990-8 Bhat, 2000, Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration, Proc. Natl. Acad. Sci. USA, 97, 11074, 10.1073/pnas.190297597 Cross, 2001, Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death, J. Neurochem., 77, 94, 10.1046/j.1471-4159.2001.t01-1-00251.x Bijur, 2000, Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium, J. Biol. Chem., 275, 7583, 10.1074/jbc.275.11.7583 Song, 2002, Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation, J. Biol. Chem., 277, 44701, 10.1074/jbc.M206047200 Carmichael, 2002, Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation, J. Biol. Chem., 277, 33791, 10.1074/jbc.M204861200 You, 2002, Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis, J. Cell Biol., 157, 429, 10.1083/jcb.200201110 Hashimoto, 2002, Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection, J. Biol. Chem., 277, 32985, 10.1074/jbc.M202803200 Li, 2000, Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta, Mol. Cell. Biol., 20, 9356, 10.1128/MCB.20.24.9356-9363.2000 Lucas, 2001, Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice, EMBO J., 20, 27, 10.1093/emboj/20.1.27 Jackson, 2002, Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila, Neuron, 34, 509, 10.1016/S0896-6273(02)00706-7 Martinez, 2002, Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation, Med. Res. Rev., 22, 373, 10.1002/med.10011 Davies, 2000, Specificity and mechanism of action of some commonly used protein kinase inhibitors, Biochem. J., 351, 95, 10.1042/0264-6021:3510095 Patel, 2002, Crystal structure of an enzyme displaying both inositol-polyphosphate-1-phosphatase and 3′-phosphoadenosine-5′-phosphate phosphatase activities, J. Mol. Biol., 315, 677, 10.1006/jmbi.2001.5271 Leclerc, 2001, Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two kinases involved in abnormal tau phosphorylation in Alzheimer's disease–A property common to most CDK inhibitors?, J. Biol. Chem., 276, 251, 10.1074/jbc.M002466200 Knockaert, 2002, Intracellular targets of paullones, J. Biol. Chem., 277, 25493, 10.1074/jbc.M202651200 Hoessel, 1999, Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases, Nat. Cell Biol., 1, 60, 10.1038/9035 Davies, 2001, Inhibitor binding to active and inactive CDK2. The crystal structure of a CDK2-cyclin A/indirubin-5-sulphonate, Structure, 9, 389, 10.1016/S0969-2126(01)00598-6 Balfour-Paul, J. (1998). Indigo. (London:British Museum Press). Maugard, 2001, Identification of an indigo precursor from leaves of Isatis tinctoria (Woad), Phytochemistry, 58, 897, 10.1016/S0031-9422(01)00335-1 MacNeil, 2001, Expression and isolation of antimicrobial small molecules from soil DNA libraries, J. Mol. Microbiol. Biotechnol., 3, 301 Gillam, 2000, Oxidation of indole by cytochrome P450 enzymes, Biochemistry, 39, 13817, 10.1021/bi001229u Cooksey, 2001, Tyrian purple, Mol., 6, 736, 10.3390/60900736 Adachi, 2001, Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine, J. Biol. Chem., 276, 31475, 10.1074/jbc.C100238200 Tang, 1992 Xiao, 2002, Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China, Leuk. Lymphoma, 43, 1763, 10.1080/1042819021000006295 Friedländer, 1909, Uber den Farbstoff des antiken Purpurs aus Murex brandaris, Angew. Chem., 22, 2492 Fouquet, 1971, Biological precursors and genesis of tyrian-purple, Angew. Chem. Int. Ed. Engl., 10, 816, 10.1002/anie.197108161 Dajani, 2001, Crystal structure of glycogen synthase kinase 3β, Cell, 105, 721, 10.1016/S0092-8674(01)00374-9 ter Haar, 2001, Structure of GSK3β reveals a primed phosphorylation mechanism, Nat. Struct. Biol., 8, 593, 10.1038/89624 Tarricone, 2001, Structure and regulation of the CDK5-p25nck5a complex, Mol. Cell, 8, 657, 10.1016/S1097-2765(01)00343-4 van Noort, 2002, Wnt signaling controls the phosphorylation status of beta-catenin, J. Biol. Chem., 277, 17901, 10.1074/jbc.M111635200 Huelsken, 2001, New aspects of Wnt signaling pathways in higher vertebrates, Curr. Opin. Genet. Dev., 11, 547, 10.1016/S0959-437X(00)00231-8 Elbi, 2002, Recruitment of dioxin receptor to active transcription sites, Mol. Biol. Cell, 13, 2001, 10.1091/mboc.13.6.mk0602002001 Hughes, 1993, Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation, EMBO J., 12, 803, 10.1002/j.1460-2075.1993.tb05715.x Dajani, 2003, Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex, EMBO J., 22, 494, 10.1093/emboj/cdg068 Shaw, 1997, Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216, FEBS Lett., 416, 307, 10.1016/S0014-5793(97)01235-0 Glinka, 1997, Head induction by simultaneous repression of Bmp and Wnt signalling in Xenopus, Nature, 389, 517, 10.1038/39092 Carnac, 1996, The homeobox gene Siamois is a target of the Wnt dorsalisation pathway and triggers organiser activity in the absence of mesoderm, Development, 122, 3055, 10.1242/dev.122.10.3055 Kessler, 1997, Siamois is required for formation of Spemann's organizer, Proc. Natl. Acad. Sci. USA, 94, 13017, 10.1073/pnas.94.24.13017 Zeng, 1997, The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation, Cell, 90, 181, 10.1016/S0092-8674(00)80324-4 Baker, 1999, Wnt signaling in Xenopus embryos inhibits bmp4 expression and activates neural development, Genes Dev., 13, 3149, 10.1101/gad.13.23.3149 Bain, 2003, The specificities of protein kinase inhibitors, Biochem. J., 371, 199, 10.1042/bj20021535 Williams, 2002, Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates, Curr. Opin. Pharmacol., 2, 567, 10.1016/S1471-4892(02)00204-7 Leost, 2000, Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25, Eur. J. Biochem., 267, 5983, 10.1046/j.1432-1327.2000.01673.x Dorronsoro, 2002, Inhibitors of glycogen synthase kinase-3, Expert Opin. Ther. Patents, 12, 1, 10.1517/13543776.12.10.1527 Bhat, 2002, GSK3beta signalling, Neurosignals, 11, 251, 10.1159/000067423 Gozes, 2002, Tau as a drug target in Alzheimer's disease, J. Mol. Neurosci., 19, 337, 10.1385/JMN:19:3:337 Hoshi, 2003, Spherical aggregates of {beta}-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3{beta}, Proc. Natl. Acad. Sci. USA, 100, 6370, 10.1073/pnas.1237107100 De Ferrari, 2003, Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils, Mol. Psychiatry, 8, 195, 10.1038/sj.mp.4001208 Inestrosa, 2002, Wnt signaling involvement in beta-amyloid-dependent neurodegeneration, Neurochem. Int., 41, 341, 10.1016/S0197-0186(02)00056-6 Phiel, 2003, GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides, Nature, 423, 435, 10.1038/nature01640 Larner, 2002, Alzheimer's disease, Mini Rev. Med. Chem., 2, 1, 10.2174/1389557023406593 Noble, 2003, Cdk5 is a key factor in tau aggregation and tangle formation in vivo, Neuron, 38, 555, 10.1016/S0896-6273(03)00259-9 Nieuwkoop, 1967 Wallace, 1995, Ligplot, Protein Eng., 8, 127, 10.1093/protein/8.2.127 DeLano, W.L. (2002). The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA. Carson, 1991, Ribbons 2.0, J. Appl. Crystallogr., 24, 958, 10.1107/S0021889891007240 Bhat, 2003, Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418, J. Biol. Chem., 278, 45937, 10.1074/jbc.M306268200 Bertrand, 2003, Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors, J. Mol. Biol., 333, 393, 10.1016/j.jmb.2003.08.031